On September 2, 2020 Nordic Nanovector ASA (OSE: NANO) reported the publication in Blood Advances, an official journal of the American Society of Hematology (ASH) (Free ASH Whitepaper), of the mature data from the LYMRIT 37-01 – Part A trial (A. Kolstad et al. – ref. below) (Press release, Nordic Nanovector, SEP 2, 2020, View Source;mature-data-from-the-lymrit-37-01—part-a-trial-published-in-blood-advances-301123613.html [SID1234564354]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data presented in this paper are aligned with the preliminary results presented by Dr Kolstad at the American Society of Hematology (ASH) (Free ASH Whitepaper) medical conference in December 2018:

Overall response rate (ORR) was 61% and complete response (CR) was 30% for all 74 patients
For patients with follicular lymphoma (FL), ORR was 65% and CR 30%
For rituximab-refractory FL, ORR was 58% and CR 19%
The publication confirms the potential of Betalutin, a single-dose radioimmunotherapy, to treat elderly, heavily pre-treated patients with relapsed/refractory indolent B-cell NHL.

There is a high unmet need for new treatment options, particularly in elderly patients with R/R follicular lymphoma (FL) and small molecule targeted therapies have so far not provided safe and effective alternatives, when chemotherapy is no longer an option. Radioimmunotherapy is an under-used option, and Betalutin may represent an attractive alternative for the treatment of relapsed/refractory FL.

Dr Arne Kolstad, Radiumhospitalet, Oslo University Hospital, commented: "The publication provides clinical data supporting the potential of Betalutin to provide an attractive single-dose treatment for relapsed/refractory FL. I am looking forward to seeing the results from the ongoing PARADIGME study, which aims to confirm the clinical benefits that this novel radioimmunotherapy can deliver."

A. Kolstad et al. Phase I/IIa study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin’s lymphoma, Blood Advances, vol. 4, issue 17, 2020, 10.1182/ bloodadvances.2020002583.
URL: ashpublications.org/bloodadvances/article/4/17/4091/463597